Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome.

导出 OA

翻译打印收藏纠错

作者： M,Chiarito ^[1] ; L,Piacente ^[1] ; N,Chaoul ^[2] ; P,Pontrelli ^[3] ; G,D'Amato ^[4] ; A,Grandone ^[5] ; G,Russo ^[6] ; M E,Street ^[7] ; M G,Wasniewska ^[8] ; G,Brunetti ^[9] ; M F,Faienza ^[10]

作者单位： Department of Biomedical Sciences and Human Oncology, Pediatric Unit, University of Bari "A. Moro", Bari, Italy. ^[1] Department of Biomedical Sciences and Human Oncology, University of Bari "A. Moro", Bari, Italy. ^[2] Department of Emergency and Organ Transplantation, Division of Nephrology, University of Bari "A. Moro", Bari, Italy. ^[3] Neonatal Intensive Care Unit, "Di Venere" Hospital, Bari, Italy. ^[4] Department of Woman, Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy. ^[5] Department of Pediatrics, IRCCS San Raffaele Hospital, Milan, Italy. ^[6] Department of Mother and Child, Azienda USL-IRCCS Di Reggio Emilia, Reggio Emilia, Italy. ^[7] Pediatric Unit, Department of Human Pathology in Adulthood and Childhood, University of Messina, Messina, Italy. ^[8] Department of Biosciences, Biotechnologies and Biopharmaceutics, University "A. Moro" of Bari, Bari, Italy. ^[9] Department of Biomedical Sciences and Human Oncology, Pediatric Unit, University of Bari "A. Moro", Bari, Italy. mariafelicia.faienza@uniba.it. ^[10]

关键词 DKK-1 RANKL Sclerostin Skeletal fragility Turner’s syndrome